The performance of Novo Nordisk and Eli Lilly, which released blockbuster diabetes and obesity drugs, have improved greatly in Q1 this year. Novo Nordisk's GLP-1 class diabetes drugs together generated KRW 10 trillion in quarterly sales. Lilly's obesity drug Zepbound posted sales of KRW 700 billion in Q1 this year, reaching nearly 1 trillion won in only half a year since its launch.

According to KoreaBio data on the 3rd, Novo Nordisk's first-quarter sales rose 24% YoY to KRW 12.886 trillion (DKK 65.349 billion). The exchange rate was based on the basic rate of exchange as of May 2.

Novo Nordisk's diabetes medicines generated sales of KRW 9.8456 trillion, up 24% YoY. In particular, sales of G